Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 113

Sort by

Sort Order Select

Journal Articles

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nassim Djebli, PhD PharmD, Felix Jaminion, MSc, Johann Laurent, MSc, Francois Mercier, PhD, Nicole A Kratochwil, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Tom Moore, MBChB, Martin Weisser, MD, Peter N Morcos, PharmD

Blood (2019) 134 (Supplement_1): 3799.

https://doi.org/10.1182/blood-2019-123712

Published: 2019

Journal Articles

Evaluating ROR1 As a Target in Childhood Leukemia

Paraskevi Diamanti, PhD, Bethan Kathleen Bailey, BSc, Obinna Ebere Iheanacho, MD, Amit C. Nathwani, MD PhD, Allison Blair, PhD

Blood (2019) 134 (Supplement_1): 2635.

https://doi.org/10.1182/blood-2019-126734

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt

Blood (2019) 134 (Supplement_1): 2871.

https://doi.org/10.1182/blood-2019-123978

Published: 2019

Journal Articles

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart ECG De Goeij, PhD, Maarten L Janmaat, PhD, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, MD, Andreas Lingnau, Andreas Freidig, Tuna Mutis, MD PhD, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van De Donk, MD PhD, Tahamtan Ahmadi, David Satijn

Blood (2019) 134 (Supplement_1): 3106.

https://doi.org/10.1182/blood-2019-125788

Published: 2019

Journal Articles

Suicide Gene Therapy with a CD33 Targeted AAV6 Vector Expressing an Inducible Caspase-9 Suicide Gene Is Therapeutic in a Xenotransplantation Model of Acute Myeloid Leukemia

Nusrat Khan, MSc, Sridhar Bammidi, Jayandharan Giridhara Rao, PhD

Blood (2019) 134 (Supplement_1): 3351.

https://doi.org/10.1182/blood-2019-125222

Published: 2019

Journal Articles

A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells

Ann Marie Rossi, MS, Anna Bunin, PhD, Lawrence Iben, BS, MA, Matthew Welsch, PhD, Tanya Berbasova, PhD, Caterina Riillo, Marco Rossi, Masaki Ohuchi, PhD, Enrique Alvarez, DVM, Naoko Kawakami, Takayuki Nagasawa, PhD, Pierfrancesco Tassone, MD, David Spiegel, MD, PhD, Luca Rastelli, PhD

Blood (2019) 134 (Supplement_1): 4411.

https://doi.org/10.1182/blood-2019-131794

Published: 2019

Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 1584.

https://doi.org/10.1182/blood-2019-123949

Published: 2019

Journal Articles

Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets

Giorgia Chiodin, Joel Allen, Philip J Rock, Enrica Antonia Martino, MD, Beatriz Valle Argos, PhD, Graham Packham, PhD, Patrick Duriez, PhD, Teunis Geijtenbeek, PhD, Carl Figdor, PhD, Richard Burack, MD PhD, Max Crispin, PhD, Freda K Stevenson, PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2019) 134 (Supplement_1): 1505.

https://doi.org/10.1182/blood-2019-127159

Published: 2019

Journal Articles

Detailed Functional Characterization of Splenic Marginal Zone Lymphoma: Uncovering Links between the Epigenetic and the Signaling Machinery

Stavroula Ntoufa, Maria Gounari, Nikos Papakonstantinou, Despoina Binou, Ioannis Tyritidis, Theodora Stivarou, Ioannis Sarrigeorgiou, Anastasia Iatrou, Niki Stavroyianni, Achilles Anagnostopoulos, Peggy Lymberi, Kostas Stamatopoulos

Blood (2019) 134 (Supplement_1): 1512.

https://doi.org/10.1182/blood-2019-127909

Published: 2019

Journal Articles

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

Alexandre Sostelly, M.Eng., PhD, Antoine Soubret, Christoph Bucher, MD, Simon Buatois, Jean-Eric Charoin, Gregor Jordan, Barbara Klughammer, PhD, Andreas Dieckmann, Taku Fukuzawa, PhD, Keisuke Gotanda, Kenji Shinomiya, Sung-Soo Yoon, MD PhD, Jens P. Panse, Junichi Nishimura, MD PhD, Alexander Röth, MD PhD, Zsolt Nagy, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 1227.

https://doi.org/10.1182/blood-2019-126911

Published: 2019

Journal Articles

A Novel Revcar Platform for Switchable and Gated Tumor Targeting

Anja Feldmann, PhD, Anja Hoffmann, Enrico Kittel-Boselli, Ralf Bergmann, PhD, Stefanie Koristka, PhD, Nicole Berndt, PhD, Claudia Arndt, PhD, Liliana Raquel Loureiro, PhD, Nicola Mitwasi, Justyna Jureczek, Martin Bornhaeuser, MD, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5611.

https://doi.org/10.1182/blood-2019-128436

Published: 2019

Journal Articles

Development of Target Modules for Early and Late Stage Cancer Treatment Using Switchable Unicar T Cell Therapy

Liliana Raquel Loureiro, PhD, Anja Feldmann, PhD, Ralf Bergmann, PhD, Nicole Berndt, PhD, Stefanie Koristka, PhD, Nicola Mitwasi, Anja Hoffmann, Justyna Jureczek, Martin Bornhaeuser, MD, Michael Bachmann, MD, Claudia Arndt, PhD

Blood (2019) 134 (Supplement_1): 5613.

https://doi.org/10.1182/blood-2019-128249

Published: 2019

Journal Articles

A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models

Anna Bunin, PhD, Katy McGrath, BS, Ann Marie Rossi, MS, Matthew Welsch, PhD, Christian Vidal, PhD, David Trinh, BA, David Spiegel, MD, PhD, Luca Rastelli, PhD, Enrique Alvarez, DVM

Blood (2019) 134 (Supplement_1): 1820.

https://doi.org/10.1182/blood-2019-130838

Published: 2019

Journal Articles

Cryo-Electron Microscopy Structure of the aIIbβ3-Abciximab Complex

Dragana Nesic, PhD, Yixiao Zhang, PhD, Aleksandar Spasic, PhD, Jihong Li, MD, Davide Provasi, PhD, Marta Filizola, PhD, Thomas Walz, PhD, Barry S. Coller, MD

Blood (2019) 134 (Supplement_1): 3617.

https://doi.org/10.1182/blood-2019-126985

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD PhD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 204.

https://doi.org/10.1182/blood-2019-129405

Published: 2019

Journal Articles

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Kirit M. Ardeshna, MBBChir, Maria A V Marzolini, Jane Norman, MD, Muhammad Al-Hajj, Simon Thomas, PhD, Jim Faulkner, Ekaterini Kotsopoulou, Martin Pule, MD, Vijay G R Peddareddigari, Nushmia Z Khokhar, Maud Jonnaert, PhD, Robert Chen, MD, Wendy Osborne, MD

Blood (2019) 134 (Supplement_1): 246.

https://doi.org/10.1182/blood-2019-122724

Published: 2019

Journal Articles

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Blood (2019) 134 (Supplement_1): 247.

https://doi.org/10.1182/blood-2019-131024

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Ann-Marie E Bröske, PhD, Ian James, PhD, Anton Belousov, PhD, Enrique Gomez, PhD, Marta Canamero, MD PhD, Chia-Huey Ooi, PhD, Nils Grabole, PhD, Sabine Wilson, PhD, Koorosh Korfi, PhD, Nicole A Kratochwil, PhD, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Denise Thomas, MSc, Natalie Dimier, PhD, Tom Moore, MBChB, Marina Bacac, PhD, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 5319.

https://doi.org/10.1182/blood-2019-123979

Published: 2019

Journal Articles

Development of a Bifunctional Checkpoint Inhibitory T Cell Engager (CiTE) to Reverse Adaptive Immune Escape in AML

Monika Herrmann, PhD, Christina Krupka, PhD, Katrin Deiser, PhD, Bettina Lindl, Ralph Mocikat, MD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Sebastian Kobold, MD, Nadja Fenn, PhD, Karl-Peter Hopfner, PhD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 4069.

https://doi.org/10.1182/blood-2018-99-119624

Published: 2018

Journal Articles

Acquisition of Mannoses on the Surface Immunoglobulin Binding Site Reveals Functional Status and Cell of Origin in Diffuse Large B Cell Lymphomas

Giorgia Chiodin, PhD, Philip Rock, Enrica Antonia Martino, MD, Beatriz Valle Argos, PhD, Graham Packham, PhD, Richard Burack, MD PhD, Freda K Stevenson, PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2018) 132 (Supplement 1): 677.

https://doi.org/10.1182/blood-2018-99-118318

Published: 2018

NARROW

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Evaluating ROR1 As a Target in Childhood Leukemia

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Suicide Gene Therapy with a CD33 Targeted AAV6 Vector Expressing an Inducible Caspase-9 Suicide Gene Is Therapeutic in a Xenotransplantation Model of Acute Myeloid Leukemia

A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets

Detailed Functional Characterization of Splenic Marginal Zone Lymphoma: Uncovering Links between the Epigenetic and the Signaling Machinery

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

A Novel Revcar Platform for Switchable and Gated Tumor Targeting

Development of Target Modules for Early and Late Stage Cancer Treatment Using Switchable Unicar T Cell Therapy

A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models

Cryo-Electron Microscopy Structure of the aIIbβ3-Abciximab Complex

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Development of a Bifunctional Checkpoint Inhibitory T Cell Engager (CiTE) to Reverse Adaptive Immune Escape in AML

Acquisition of Mannoses on the Surface Immunoglobulin Binding Site Reveals Functional Status and Cell of Origin in Diffuse Large B Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only